Trial Profile
Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 19 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.